Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GW 405833 (L-768242) 是一种大麻素 2 (CB(2)) 受体选择性激动剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 328 | 现货 | ||
2 mg | ¥ 483 | 现货 | ||
5 mg | ¥ 828 | 现货 | ||
10 mg | ¥ 1,230 | 现货 | ||
25 mg | ¥ 2,230 | 现货 | ||
50 mg | ¥ 3,390 | 现货 | ||
100 mg | ¥ 4,930 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 917 | 现货 |
产品描述 | GW 405833 (L-768242) is an agonist of cannabinoid-2 (CB(2)) receptor-selective |
体内活性 | GW405833 (3, 10, and 30 mg/kg i.p.) dose dependently reversed established mechanical allodynia in both pain models in WT mice;?however, the antiallodynic effects of GW405833 were fully preserved in CB2KO mice and absent in CB1KO mice.?Furthermore, the antiallodynic efficacy of GW405833 (30 mg/kg i.p.) was completely blocked by the CB1 antagonist rimonabant (10 mg/kg i.p.) but not by the CB2 antagonist SR144528 (10 mg/kg i.p.).?Thus, the antinociceptive properties of GW405833 are dependent on CB1 receptors.?GW405833 (30 mg/kg i.p.) was also inactive in a tetrad of tests measuring cardinal signs of CB1 activation.?Additionally, unlike rimonabant (10 mg/kg i.p.), GW405833 (10 mg/kg, i.p.) did not act as a CB1 antagonist in vivo to precipitate withdrawal in mice treated chronically with Δ9-tetrahydrocannabinol[1]. |
动物实验 | Baseline mechanical paw withdrawal thresholds were measured in each paw for each animal before performing either PSNL or injecting CFA.?Another predrug baseline was then taken after painful peripheral neuropathy or inflammatory pain was fully established.?GW405833 was administered (i.p.) 30 minutes before evaluation of the impact of drug manipulations on mechanical paw withdrawal thresholds.?Different doses of GW405833 were injected (i.p.) within subjects in the order of vehicle (0), 3, 10, and 30 mg/kg.?Sufficient time was allowed to lapse between each dose to verify that mechanical paw withdrawal thresholds returned to the predrug levels before dose escalation. .?In the groups where CB1 or CB2 antagonists were tested, rimonabant or SR144528 (10 mg/kg i.p.) was administered 20 minutes before GW405833 injection[1]. |
别名 | L-768242, 1-(2,3-二氯苯甲酰基)-5-甲氧基-2-甲基-3-[2-(4-吗啉基)乙基]-1H-吲哚 |
分子量 | 447.35 |
分子式 | C23H24Cl2N2O3 |
CAS No. | 180002-83-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10 mg/mL (22.35 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2354 mL | 11.1769 mL | 22.3539 mL | 55.8847 mL |
5 mM | 0.4471 mL | 2.2354 mL | 4.4708 mL | 11.1769 mL | |
10 mM | 0.2235 mL | 1.1177 mL | 2.2354 mL | 5.5885 mL | |
20 mM | 0.1118 mL | 0.5588 mL | 1.1177 mL | 2.7942 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
GW 405833 180002-83-9 GPCR/G Protein Cannabinoid Receptor GW-405833 L768242 L-768242 L 768242 GW405833 1-(2,3-二氯苯甲酰基)-5-甲氧基-2-甲基-3-[2-(4-吗啉基)乙基]-1H-吲哚 anti-inflammatory Inhibitor neuropathic pain inhibit inhibitor